- Original article
- Open Access
Neutrophil gelatinase-associated lipocalin as a biomarker for predicting acute kidney injury after coronary artery bypass grafting
Ain-Shams Journal of Anesthesiology volume 13, Article number: 5 (2021)
Early and precocious determination of acute kidney injury (AKI) is essential to prevent morbidity and mortality following coronary artery bypass grafting (CABG). Evaluation of the perioperative renal function is substantial using novel biomarkers other than the late traditional method of using serum creatinine. Plasma neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker investigated for early detection of AKI in patients undergoing coronary artery bypass grafting, and its role has to be determined in this study.
Twenty-five patients undergoing elective CABG were enrolled in this cohort study and were assigned into two groups: group I include the patients that did not develop AKI (no AKI group) and group II include the patients that developed AKI (AKI group). Acute kidney injury based on Kidney Disease: Improving Global Outcomes (KDIGO) classification had been developed in 7 patients (28%). Plasma NGAL levels at 6 h were higher in patients who developed AKI compared with those who did not (302 ± 88.02 vs. 116.50 ± 17.33 ng/m, p value < 0.001). The cut-off value of plasma NGAL levels measured 6 h postoperatively was 145 ng/ml and the area under the receiver-operating characteristic (ROC) curve was 0.965. Results of this study showed that plasma NGAL is a robust early biomarker of AKI, which preceded the rise in serum creatinine by many hours.
This study revealed that earlier diagnosis of acute kidney injury in patients undergoing CABG can be achieved by measuring postoperative plasma NGAL concentration at 6 h.
Acute kidney injury (AKI) is a frequent intricacy after cardiac surgery. Cardiac surgery-associated kidney injury may affect 30% of the patients based on the literature and different definitions of acute kidney injury. Mortality increases from 1% up to half the patients who undergo hemodialysis following cardiac surgery (Thiele et al. 2015). AKI that follows CABG affects long-term survival negatively, even in patients with minor kidney dysfunction (Bouma et al. 2018).
Early identification of renal dysfunction is considered the most effective method to decrease the morbidity of postoperative AKI by permitting early diagnostic and therapeutic interventions to forestall renal failure development (Bataille et al. 2017).
Several hazard factors have been recognized to augment the incidence of AKI associated with cardiac surgery, including age, chronic hypertension, diabetes, and peripheral vascular disease are prevalent unmodifiable risk factors (Lopez-Delgado et al. 2013).
Other risk factors like utilization of cardiopulmonary bypass (CPB), transfusion of blood products (packed RBCs and fresh frozen plasma), and nephrotoxic drugs administration before or after surgery may as well increase the risk of postoperative AKI (Ostermann and Liu 2017).
Over the last decades, many endeavors have been made to seek out explicit biomarkers having the ability to anticipate acute damage of the epithelium of kidney tubules (Schrezenmeier et al. 2017).
Serum creatinine level has been accustomed to figure out changes in renal function for the past five decades. The half-life of serum creatinine in normal adult male is 4 h. After 50% decrease in creatinine clearance, the half-life of serum creatinine is around 8 h and it takes another three to five half-lives to reach peak level and reaching a steady state (it takes 24 to 40 h). This drawback causes serum creatinine to be a late marker for AKI even after decline in the glomerular filtration rate (GFR) to half (Srisawat and Kellum 2020).
Furthermore, the level of serum creatinine is affected by various factors, like gender, aging, the mass of the muscle, protein metabolism, medications, and fluid intake and deficit (Jain et al. 2016).
Because of the failure of the existing markers, more novel and reliable biomarkers that could work as ‘the kidney troponin’ should be considered, which may allow early identification of the damage of renal tubules, apart from the decrease in function (Abdallah et al. 2013).
Many novel biomarkers have been evaluated as possible biomarkers for early and meticulous AKI identification. These include biomarkers like NGAL that can be detected in plasma and urine, cystatin C which is detected in plasma, and urinary biomarkers like kidney injury molecule-1, urine NGAL, and interleukin-18 (de Geus et al. 2012).
NGAL is considered to be one of the most investigated AKI biomarkers. NGAL, otherwise known as Lipocalin-2, is a 25-kDa protein with 178 amino acids. Plasma NGAL is produced by neutrophils and filtered by the glomeruli freely and afterward completely reabsorbed by the proximal convoluted tubules (Chew and Hwang 2019). Expression of NGAL is induced by tissue injury and its expression is quite prompt, usually within 2–4 h of injury. Fortunately, NGAL is very stable and easily detected in serum and urine (Kashani et al. 2017).
NGAL was recently proposed as a portentous early predictive biomarker for kidney injury (Rysz et al. 2017).
This prospective cohort study was conducted in Ain Shams University hospitals from January 2019 to December 2019.
After ethical committee approval, written informed consent had been taken from 25 participants of either sex with normal preoperative creatinine level (0.6–1.2 mg/dl), scheduled for elective coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).
Exclusion criteria included: age < 18 years, emergency surgery, Redo operations, pre-existing renal impairment, or renal replacement therapy (RRT), low ejection fraction < 30%, the need for postoperative intra-aortic balloon, chronic inflammatory disorders and immunosuppression, corticosteroid therapy, and patient refusal.
Demographic data, patients’ risk factors, preoperative evaluation of all the patients enrolled in the study and preoperative routine laboratory test as coagulation profile, CBC, kidney function, and liver function tests were evaluated and recorded. All the patients continued the preoperative medications till the night of surgery with the exception of nephrotoxic drugs. Upon arrival to the operating room, peripheral venous cannula was inserted and radial artery cannulation was done in the non-dominant hand under local anesthesia after checking the patency of the collaterals through the modified Allen’s test. Two milligrams midazolam and 4 mg morphine IV were given for sedation after application of standard monitors to the patient according to the American Society of Anesthesiologist (ASA) recommendations. Induction of anesthesia was done using fentanyl at 5 μg/kg, midazolam at 0.05 mg/kg (titrated dose), thiopental at 3–5 mg/kg (titrated dose), and rocuronium at 0.9 mg/kg to achieve muscle relaxation in order to facilitate tracheal intubation. Blood pressure was maintained within 20% of the baseline with avoiding tachycardia (keeping HR between 60–80 bpm) during induction. Maintenance of anesthesia was done by isoflurane (1.2%), fentanyl and rocuronium.
Rt. Central venous line was inserted by the guidance of ultrasound.
Anticoagulation was done before cannulation of the aorta using intravenous heparin 300 to 400 units/kg with target ACT between 400 and 480 s.
After clamping of the aorta, antegrade cold cardioplegia (each 1 L ringer solution contained 30 mmol/l potassium chloride, 100 mg lidocaine, and 1 gm magnesium sulfate) was administered in a dose 10 mg/kg. Cardioplegia was given in a dose of 5 mg/kg every 20 minutes.
CPB was established to keep the mean arterial pressure (MAP) during full flow between 50 and 70 mmHg. Hematocrit was kept above 20%, fresh packed RBCs were given if needed. CBP time and aortic cross-clamping time were measured and recorded.
Patients were weaned from the CPB according to the general condition of the patient and cross-clamp time. After venous and arterial decannulation, protamine was administered for reversal of heparin (1 mg per 100 units of totally administered heparin, slowly to avoid hypotension). The patients enrolled in the study were weaned from the ventilator in the intensive care unit (ICU) after vital data stabilization (MAP above 60 mmHg to 90 mmHg, heart rate (HR) within normal range above 60 and below 90 bpm and central venous pressure (CVP) within the range of 10 and 15 cm H2O) and fulfillment of the criteria for extubation. Patients were followed up and managed for the 48 h study period as per standard protocols.
NGAL levels were determined at two time points: preoperatively (within 24 h before the surgery) and postoperatively 6 h after arrival to the ICU. Assay of serum NGAL was done by the enzyme-linked immune sorbent assay (ELISA) method, using the kit supplied by Shanghai Sunred Biological Technology Co., Ltd. The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA).
Serum creatinine levels were measured at five time points: preoperatively before induction of anesthesia and at 6, 12, 24, and 48 h postoperative. Serum creatinine concentration was measured using a Beckman® Analyzer (Beckman Coulter, Brea, CA, USA) according to the picric acid colorimetric method.
Postoperative AKI during the 48 h follow-up period was determined based on the Kidney Disease: Improving Global Outcomes (KDIGO) classification and the levels of the 6 h postoperative plasma NGAL values for renal impairment were checked. Other variables we included were age, gender, aortic cross clamp time, and CPB time.
Stages of AKI based on KDIGO classification (Khwaja 2012)
Stage 1 AKI was defined as rise in serum creatinine by 0.3 mg/dL or by an increase ≥ 1.5-fold from the baseline value
Stage 2 AKI classified by a 2–2.9-fold rise in baseline serum creatinine
Stage 3 AKI by ≥ 3-fold rise in serum creatinine.
The primary outcome of this study was to evaluate the efficiency of neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker in predicting AKI in patients scheduled for elective coronary artery bypass grafting (CABG) under cardiopulmonary bypass (CPB).
Using MedCalc program version 11 setting alpha error at 5% and power 90% results from previous study, (Prabhu et al. 2010) showed a significant correlation between neutrophil gelatinase-associated lipocalin (NGAL) and change in serum creatinine (r = 0.8). Based on this and taking in consideration 15% drop out rate, the needed sample is 25 patients.
This study was done as a prospective cohort study, in which 25 patients included.
The patients were assigned into two groups:
Group I include the patients that did not develop AKI (no AKI group)
Group II include the patients that developed AKI (AKI group)
Statistical package and analysis
The data was collected, revised, coded, and introduced to a PC using statistical package for social science (SPSS 20.0. for windows; Armonk, NY: IBM Corp., 2010). Data was presented as mean and standard deviation (±SD) for quantitative prometric data. Independent t test was used to compare quantitative variables between the two study groups when the data were normally distributed. Qualitative data were presented as number and percentage and the differences between the two groups were compared using the chi-square (χ2) test and/or Fisher exact test when the expected count in any cell found less than 5. p < 0.05 will be considered significant.
Pearson correlation coefficient was used to test correlations between serum NGAL and other variables.
The receiver operating characteristic (ROC) curve and area under the curve (AUC; with 95% confidence intervals [CIs]) of plasma NGAL measured 6 h postoperatively were calculated and compared for the assessment of its ability to anticipate acute kidney injury.
Twenty-five patients without pre-existing renal dysfunction undergoing elective on pump CABG who did not have exclusion criteria were enrolled in this prospective cohort study.
The kidney injury was determined based on kidney disease improving global outcomes (KDIGO) classification in terms of rise in serum creatinine during the first 2 days after surgery.
Of the 25 patients studied, 7 (28%) had AKI postoperatively as defined by KDIGO criteria while 18 (72%) did not, by measuring serum creatinine (SCr) 48 h postoperatively.
Six patients who had AKI developed stage 1 AKI while only one patient had stage 2 AKI. None of the patients of AKI group developed stage 3 AKI or underwent dialysis.
Average age was 56.54 ± 6.44 years in No AKI Group vs. 60.67 ± 4.51 years in AKI Group with (p value 0.136)
There is statistically non-significant difference between AKI group and No AKI group as regards age and sex where p value was > 0.05 (p value 0.284).
Patients’ characteristics regarding body mass index, medical history of diabetes mellitus, familial history of coronary artery disease (CAD), history of dyslipidemia, diuretics use before surgery, preoperative hemoglobin, and preoperative left ventricular systolic function were comparable in both groups (Table 1)
The number of hypertensive patients in the AKI group (85%) compared to the no AKI group (33%) was significantly higher (p value = 0.019)
AKI group had a longer ICU stay compared to the no AKI group
There is no statistical difference as regards preoperative serum creatinine and serum NGAL levels between the two groups where p value was > 0.05 (Table 1)
Patients with AKI had longer CPB time (109.42 ± 7.48 vs. 84.00 ± 6.87 min) (p value < 0.001) and longer aortic cross-clamp time (93.86 ± 6.77 vs. 69.4 ± 6.49 min) (p value < 0.001) compared to the other group (Table 2).
No significant difference between SCr (p value > 0.05) in the two groups for preoperative levels and postoperative creatinine levels at 6, 12, and 24 h. The AKI group had higher postoperative 48 h SCr levels (p < 0.001) as shown in (Fig. 1).
Measurement of plasma NGAL 6 h postoperatively showed higher levels in patients who had AKI during the first 2 days follow-up vs those who did not (302 ± 88.02 vs. 116.50 ± 17.33 ng/mL) (p value < 0.001) as shown in Fig. 2.
In the AKI group, there is strong positive correlation between 6 h serum NGAL levels and serum creatinine levels measured 48 h after surgery(r = 0.857) (p value = 0.014) (Table 3)
The cut-off value of the 6 h postoperative plasma neutrophil gelatinase-associated lipocalin levels was 145 ng/ml and the area under the receiver-operating characteristic curve was 0.965 as shown in Fig. 3. The sensitivity, specificity, and negative and positive predictive values of plasma NGAL after 6 h of operation in early detection of kidney injury in the postoperative 2 days period were found to be 100%, 88.9%, 100%, and 77.8%, respectively (Table 4)
Acute kidney injury following cardiac surgery is a frequent and serious complication, it is considered to be independently associated with worse outcomes, increased mortality rate, prolonged ICU, and hospital stay (Harky et al. 2020).
Serum creatinine increases only when more than 50% of renal function is lost; in addition, several factors influence creatinine levels making it an inadequate marker for AKI (Srisawat and Kellum 2020). Therefore, there is a crucial need for more accurate and reliable biomarkers that might result in early prediction of AKI and therefore help timely initiation of appropriate therapeutic interventions or applying preventive measures.
In several preclinical and clinical studies, NGAL showed promising performance in detecting AKI hours earlier than serum creatinine and was postulated to be the “troponin” of the kidneys (Abdallah et al. 2013).
This prospective cohort study was done in Ain Shams University Hospitals for a period of 1 year. Twenty-five patients scheduled for elective CABG were enrolled in this study.
Four (16%) women and 21 (84%) men patients were enrolled in the study. The mean age was 57.69 ± 6.17 years.
In all patients enrolled in our study, serum NGAL was measured at two time points: preoperative within 24 h before surgery and 6 h postoperatively in all patients enrolled in this study
Serum creatinine was measured preoperatively at 6 h, 12 h, 24 h, and 48 h after surgery.
A total of 7 patients out of 25 (28%) developed AKI according to Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO criteria, plasma NGAL levels at 6 h postoperative were significantly higher in all patients with AKI compared to their baseline levels, whereas only one patient had elevated serum creatinine at 6 h postoperative.
Our data suggests that plasma NGAL is a robust early AKI biomarker, which forgoes the rise in serum creatinine by many hours allowing the avoidance of nephrotoxic drugs (antibiotics and nonsteroidal anti-inflammatory drugs) and dose adjustment of the antibiotics; therefore, decreasing the morbidity and the necessity of RRT.
Plasma NGAL measured 6 h postoperatively showed higher levels in patients who had AKI during the first 2 days follow-up vs those who did not (302 ± 88.02 vs. 116.50 ± 17.33 ng/mL) (p value < 0.001). In AKI group, there was a statistically significant correlation between 6 h NGAL level and creatinine measured 48 h after surgery (r = 0.859) (p value = 0.014)
The ROC analysis of this study revealed that the cut-off values for NGAL measured 6 h after procedure was 145 ng/mL and the AUC for the ROC curve was 0.965, with sensitivity (100%) and specificity (88.9%).
Our results are in line with several previous studies that suggested NGAL as a highly promising biomarker for predicting AKI early after cardiac operations.
Mishra et al. measured NGAL levels in the pediatric population undergoing cardiac surgery and reported that serum NGAL showed a 10-fold increase 2 h postoperative in patients who developed AKI later (Mishra et al. 2005). Further studies were performed in children undergoing cardiac surgical procedures: Dent et al. showed comparable finding by demonstrating a significant rise of plasma NGAL at 3 h after CPB (Dent et al. 2007). Fadel et al. also found that plasma NGAL measurements may be efficient for early detection of kidney damage triggered by CPB (Fadel et al. 2012).
Our findings were also similar to that of the study carried out by Miah et al., that demonstrated that plasma NGAL level 6 h after completion of cardiac valve surgery increased prior to serum creatinine level rise and thus AKI can be detected earlier by plasma NGAL (Miah et al. 2018).
In agreement with our study, Tuladhar et al. found that there was a marked rise in plasma NGAL level in all participants and this increase in the levels after cardiac surgery was significantly higher in patients with AKI in comparison to those without AKI (Tuladhar et al. 2009).
Similar results were observed in the prospective cohort study done by Haase et al. on adult patients at risk of AKI due to cardiac surgery and other causes, they found that plasma NGAL 6 h after CPB fulfilled several criteria of a promising renal biomarker and the increase in plasma NGAL preceded the rise in serum creatinine or the clinical diagnosis of AKI (Haase et al. 2011).
Recent studies have provided important findings about cut-off values consistent with this study; Ghonemy and Amro found that the sensitivity and specificity of serum NGAL at 3 h after the end of surgery was 94.1% and 93.9% respectively. After 6 h post-operative, NGAL sensitivity increased to 98.1% with minor decline in the specificity to 91.9% (Ghonemy and Amro 2014).
Similarly, Park et al. found that plasma NGAL levels were significantly increased early at immediate postoperative ICU admission, while serum creatinine showed no significant increase. They determined serum NGAL cut-off value of 165.5 ng/ml on ICU admission with 61.5% sensitivity and 88.9% specificity (Park et al. 2015).
Similar results were reported by Parikh et al., and they revealed that peak plasma NGAL levels were throughout the first 6 h following surgery. Elevated plasma NGAL levels significantly predicted which patients were at higher risk of developing AKI, with area under the receiver-operating characteristic (AUC) curve of 0.75 (Parikh et al. 2011).
Another study conducted on patients with chronic kidney impairment scheduled for cardiac surgery; Perrotti and his colleagues found that serum NGAL levels greater than 155 ng/ml, measured 6 h after CPB were considered to be independent predictor of AKI, with a sensitivity of 79% and specificity of 58%, suggesting that its predictive value is not affected by baseline renal function (Perrotti et al. 2015).
There was also another study in accordance with this result as in study proclaimed by Prabhu et al. that found that plasma NGAL measurement in patients 4 h following CPB predicted AKI at a cut-off value 229 ng/mL with an area under the curve of 0.98 (Prabhu et al. 2010).
In the meta-analysis done by Zhou et al. including 24 cohort studies (22 prospective and 2 retrospective studies), NGAL level measured within 6 h postoperative was an adequate biomarker for early detection of AKI (Zhou et al. 2016).
However, conflicting data to our results were reported by Friedrich et al. they included 81 patients undergoing CBP and conducted that although NGAL values increased postoperatively, the peak values failed to prognosticate the development of AKI or the severity of injury (Friedrich et al. 2017). Similarly, Perry et al. found that the increase in plasma NGAL levels was associated with AKI; however, its utility was limited due to its low sensitivity (38.7%) (Perry et al. 2010). Different explanations for these contradicting conclusions may be the difference in the timing of sampling, patients’ demographics and comorbidities, and the AKI definition used in these studies.
Our study emphasized that prolonged CPB time is associated with occurrence of AKI postoperatively, as mentioned by Boldt et al. who stated that patients with cardiopulmonary bypass time greater than 90 min showed greater kidney injury than patients with bypass time less than 70 min (Boldt et al. 2003).
Also Karim et al. found that the incidence of AKI increased along with the rise in the CPB and cross clamp time significantly. The CPB time more than seventy minutes increased the AKI hazard by an odds ratio (OR) 4.76 as compared to 71–140 min and by an OR 6.30 for > 140 min (p value < 0.01) while for the cross clamp time more than 60 min increased the AKI hazard by an OR of 2.84 as compared to 61–120 min and by an OR 3.64 for > 120 min (p = 0.01) (Karim et al. 2017).
The small group number (n = 25) included in the study is considered to be an important limitation. To evaluate the ability of plasma NGAL for earlier diagnosis of AKI after coronary artery bypass grafting, larger randomized prospective trials are required.
The other limitation of this study is that the plasma NGAL level was assessed at 6 h postoperatively and not after that, which is considered a short observational period. In spite of the fact that earlier studies on NGAL have showed that AKI and the elevation of plasma NGAL levels occur in the majority of studies during the aforementioned period.
Despite normal serum creatinine levels before surgery for all the patients enrolled in the study, measurement of the glomerular filtration rate before surgery to evaluate kidney function was not done.
This study revealed that early prediction of acute kidney injury in patients undergoing CABG can be achieved by monitoring plasma NGAL levels at baseline and 6 h after surgery. The early rise in plasma NGAL levels, preceding serum creatinine can be beneficial in providing an early warning to critical care providers allowing the possibility of taking earlier interventions in this high risk population.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Acute kidney injury
American Society of Anesthesiologist
Coronary artery bypass grafting
Coronary artery disease
Central venous pressure
Glomerular filtration rate
Kidney Disease: Improving Global Outcomes
Left ventricular ejection fraction
Mean arterial pressure
Neutrophil gelatinase-associated lipocalin
Receiver operating characteristic
Renal replacement therapy
Abdallah E, Waked E, Al-Helal B, Asad R, Nabil M, Harba T (2013) Novel troponin-like biomarkers of acute kidney injury. Saudi J Kidney Dis Transpl 24(6):1111
Bataille A, Tiepolo A, Robert T, Boutten A, Longrois D, Dehoux M, Provenchere S (2017) Reference change values of plasma and urine NGAL in cardiac surgery with cardiopulmonary bypass. Clin Biochem 50(18):1098–1103
Boldt J, Brenner T, Lehmann A, Suttner SW, Kumle B, Isgro F (2003) Is kidney function altered by the duration of cardiopulmonary bypass? Ann Thorac Surg 75(3):906–912
Bouma HR, Mungroop HE, de Geus AF, Huisman DD, Nijsten MW, Mariani MA, Scheeren TW, Epema AH (2018) Acute kidney injury classification underestimates long-term mortality after cardiac valve operations. Ann Thorac Surg 106(1):92–98
Chew STH, Hwang NC (2019) Acute kidney injury after cardiac surgery: a narrative review of the literature. J Cardiothorac Vasc Anesth 33(4):1122–1138
de Geus HR, Betjes MG, Bakker J (2012) Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J 5(2):102–108
Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P (2007) Plasma NGAL predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 11(6):R127
Fadel FI, Rahman AMA, Mohamed MF, Habib SA, Ibrahim MH, Sleem ZS, Bazaraa HM, Soliman MM (2012) Plasma neutrophil gelatinase-associated lipocalin as an early biomarker for prediction of acute kidney injury after cardio-pulmonary bypass in pediatric cardiac surgery. Arch Med Sci 8(2):250
Friedrich MG, Bougioukas I, Kolle J, Bireta C, Jebran FA, Placzek M, Tirilomis T (2017) NGAL expression during cardiopulmonary bypass does not predict severity of postoperative acute kidney injury. BMC Nephrol 18(1):73
Ghonemy TA, Amro GM (2014) Plasma neutrophil gelatinase-associated lipocalin (NGAL) and plasma cystatin C (CysC) as biomarker of acute kidney injury after cardiac surgery. Saudi J Kidney Dis Transpl 25(3):582
Haase M, Haase-Fielitz A, Bellomo R, Mertens PR (2011) Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 18(1):11–18
Harky A, Joshi M, Gupta S, Teoh WY, Gatta F, Snosi M (2020) Acute Kidney Injury Associated with Cardiac Surgery: a Comprehensive Literature Review. Braz J Cardiovasc Surg 35(2):211–224
Jain V, Mehta Y, Gupta A, Sharma R, Raizada A, Trehan N (2016) The role of neutrophil gelatinase-associated lipocalin in predicting acute kidney injury in patients undergoing off-pump coronary artery bypass graft: A pilot study. Ann Card Anaesth 19(2):225
Karim HMR, Yunus M, Saikia MK, Kalita JP, Mandal M (2017) Incidence and progression of cardiac surgery-associated acute kidney injury and its relationship with bypass and cross clamp time. Ann Cardiac Anaesth 20(1):22
Kashani K, Cheungpasitporn W, Ronco C (2017) Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med 55(8):1074–1089
Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179–c184
Lopez-Delgado JC, Esteve F, Torrado H, Rodríguez-Castro D, Carrio ML, Farrero E, Javierre C, Ventura JL, Manez R (2013) Influence of acute kidney injury on short-and long-term outcomes in patients undergoing cardiac surgery: risk factors and prognostic value of a modified RIFLE classification. Crit Care 17(6):R293
Miah OF, Dowel FA, Latif A, Hai AN, Mahmud MA, Razzak MA, Ahammod T (2018) NGAL (Neutrophil Gelatinase-associated Lipocalin) is an Early Predictor of Acute Kidney Injury after Cardiac Surgery and Variation of NGAL Values in Homogenous Study Subject. Mymensingh Med J 27(1):212–215
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365(9466):1231–1238
Ostermann M, Liu K (2017) Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol 31(3):305–314
Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD (2011) Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 22(9):1748–1757
Park CM, Kim JS, Moon HW, Park S, Kim H, Ji M, Hur M, Yun YM (2015) Usefulness of plasma neutrophil gelatinase-associated lipocalin as an early marker of acute kidney injury after cardiopulmonary bypass in Korean cardiac patients: a prospective observational study. Clin Biochem 48(1-2):44–49
Perrotti A, Miltgen G, Chevet-Noel A, Durst C, Vernerey D, Bardonnet K, Davani S, Chocron S (2015) Neutrophil gelatinase-associated lipocalin as early predictor of acute kidney injury after cardiac surgery in adults with chronic kidney failure. Ann Thorac Surg 99(3):864–869
Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Shernan SK, Body SC (2010) Plasma neutrophil gelatinase-associated lipocalin and acute postoperative kidney injury in adult cardiac surgical patients. Anesth Analg 110(6):1541
Prabhu A, Sujatha DI, Ninan B, Vijayalakshmi MA (2010) Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Vasc Surg 24(4):525–531
Rysz J, Gluba-Brzózka A, Franczyk B, Jabłonowski Z, Ciałkowska-Rysz A (2017) Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci 18(8):1702
Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM (2017) Biomarkers in acute kidney injury–pathophysiological basis and clinical performance. Acta Physiol 219(3):556–574
Srisawat N, Kellum JA (2020) The role of biomarkers in acute kidney injury. Crit Care Clin 36(1):125–140
Thiele RH, Isbell JM, Rosner MH (2015) AKI associated with cardiac surgery. Clin J Am Soc Nephrol 10:500–514
Tuladhar SM, Püntmann VO, Soni M, Punjabi PP, Bogle RG (2009) Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 53(3):261–266
Zhou F, Luo Q, Wang L, Han L (2016) Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis. Eur J Cardiothorac Surg 49(3):746–755
Ethics approval and consent to participate
Approval of research ethical committee of Faculty of Medicine, Ain-Shams University was obtained (code number: FMASU M D 257/2018) and written informed consent was obtained from patients’ legal guardian(s) after description of the procedure and its potential complications.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Othman, H.M.E.D.M., Hassan, A.E.M., Elsersi, M.H. et al. Neutrophil gelatinase-associated lipocalin as a biomarker for predicting acute kidney injury after coronary artery bypass grafting. Ain-Shams J Anesthesiol 13, 5 (2021). https://doi.org/10.1186/s42077-020-00123-5
- Acute kidney injury
- Serum creatinine
- Neutrophil gelatinase-associated lipocalin
- Cardiac surgery